Patients with psychotic disorders regularly use natural medicines, although it is unclear whether these are effective and safe. The aim of this study was to provide an overview of evidence for improved outcomes by natural medicines. A systematic literature search was performed through Medline, PsycINFO, CINAHL, and Cochrane until May 2015. In 110 randomized controlled trials, evidence was found for glycine, sarcosine, N-acetylcysteine, some Chinese and ayurvedic herbs, ginkgo biloba, estradiol, and vitamin B6 to improve psychotic symptoms when added to antipsychotics. Ginkgo biloba and vitamin B6 seemed to reduce tardive dyskinesia and akathisia. Results on other compounds were negative or inconclusive. All natural agents, except reserpine, were well tolerated. Most study samples were small, study periods were generally short, and most results need replication. However, there is some evidence for beneficial effects of certain natural medicines.
D
espite much progress in treatment options in the last century, the pharmacological treatment of psychotic disorders is often unsatisfactory, as expressed in persistent positive, negative, cognitive and affective symptoms, and problems in social functioning (Kane and Correll, 2010) . Psychotic symptoms are often only partially resolved (Rummel-Kluge et al., 2010) , especially cognitive and negative symptoms (Buckley and Stahl, 2007) . Apart from clozapine, second-generation antipsychotics are generally as effective as first-generation antipsychotics for positive symptoms, but the promise of greater efficacy for negative symptoms has not been fulfilled (Leucht et al., 2012) . Many patients continue experiencing persistent symptoms and relapses during treatment with antipsychotics, particularly when they fail to adhere to prescribed medications (Van Os and Kapur, 2009) . Psychiatric medication adherence is a problem because many patients do not want them or consider them unnecessary (Cooper et al., 2007) , or experience undesired adverse effects (Pai and Vella, 2012) . For antipsychotics, these adverse effects include weight gain, sexual dysfunction, glycemic and lipid dysfunction, extrapyramidal symptoms (EPS), and sedation (Stahl, 2008) .
Many patients with psychotic disorders use nonconventional medicines or treatments in the hope of decreasing undesired adverse effects or a more successful recovery (Hazra et al., 2010; Stevinson, 2001) . Nonconventional medicine includes therapeutic lifestyle changes and complementary and alternative medicine (CAM) (Hoenders, 2013) . Complementary medicine comprises diagnostics, treatments, and prevention strategies based on theories accepted in biomedicine and substantiated by some scientific evidence (two or more randomized controlled trials [RCTs] ), but for various (cultural or practical) reasons are no part of biomedicine (Hoenders et al., 2011) . Alternative medicine comprises diagnostics, treatments, and prevention strategies using other than the basic concepts of biomedicine. So far, there is little proof for the efficacy of the latter treatments and/or considerable controversy about their scientific validation (Lake, 2007) . Natural medicine is part of complementary medicine, using agents produced by living organisms (plant, tree, seed, vegetable, fruit, animal, and human) instead of nonnatural (i.e., chemical) agents only being obtained from laboratory experiments (Porter, 1998) . Some patients prefer natural medicines, assuming that natural is better and will cause fewer adverse effects. This is obviously not (always) true, as the natural environment contains agents that can be toxic to humans. The molecular structure and dosage of a substance rather than its source determine its effect on human health (Topliss et al., 2002) . Besides, herbal medicines can cause undesired effects including interactions with prescription medication (Ernst, 2003a (Ernst, , 2003b . Hazra et al. (2010) reported a lifetime and 1-year prevalence rate of CAM use in Canadian psychotic outpatients of 88% and 68%, respectively. A major difficulty these patients encounter is the heterogeneity in treatment options with CAM, ranging from possibly interesting agents to useless, or even dangerous, ones (Ernst, 2003b) . For instance, the concomitant use of antipsychotics and Chinese herbs was found to induce significantly improved clinical outcomes compared with antipsychotics only (Rathbone et al., 2007) . However, a small but significant number of patients concomitantly treated with Chinese herbs have a greater risk of developing worse outcomes (Zhang et al., 2011b) .
In recent years, patients' preferences and views have received more attention in making treatment choices (e.g., shared decision making [Elwyn et al., 2000] and "patient-centered care" [Gill, 2013] ). The introduction of patient's choice in deciding which antipsychotic to choose has been proposed (Morrison et al., 2012) . However, it is difficult for both patients and physicians to make informed decisions in the absence of reliable information on the emerging evidence for CAM or natural medicine. Considering its high usage in psychotic patients, there is an urgent need for readily available scientific information.
This article reviews the literature on the efficacy and safety of natural medicines for psychotic disorders. Medline  511  629  1140  CINAHL  62  22  84  PsycINFO  245  129  374  Cochrane  253  20  273  Total  1069  800  1871  Total deduplicated  1467 (controlled) trials; b) mechanism studies exploring the effects of natural medicines; c) animal studies; d) affective disorders/other disorders/no disorder/(relapse) prevention; e) conference abstracts; f) book chapters; g) clinical trial registrations; h) comments, addenda, corrigenda, and letters; i) non-English languages (e.g., Chinese, Japanese, Hebrew, German, and Spanish); and (j) duplicate hits that had not been removed systematically. Second, two authors (H.J.R.H. and A.A.B.V.) independently indicated whether papers-based on the abstracts-should (possibly) be included. Consultation followed about dubious cases and in case of discordance. Thereupon, 427 studies remained, of which the full papers on RCTs were retrieved and studied. Of these, another 160 were excluded. A flowchart of the study selection is presented in Figure 1 . We found 147 reviews and checked whether RCTs in their reference lists matching our inclusion criteria were included. Eight RCTs with a Jadad score of 3 or higher (see paragraph on risk of bias assessment and Table 2) found through cross-references were added. Eighteen RCTs were excluded because of a Jadad score less than 3. The reviews (not shown in Table 3 ) will be contrasted to our findings in the Discussion section.
Classification of Agents
The RCTs included were divided into six groups based on supposed underlying mechanisms of action (Table 3) . For a good grasp of the results, we briefly present the working mechanisms of the agents from five groups (not from the group "other substances").
(i) Omega-3 fatty acids. Polyunsaturated fatty acids (PUFAs) are essential for brain functioning (Tsalamanios et al., 2006) . They have multiple important biological roles, including membrane functioning, neurotransmission, signal transduction, and eicosanoid synthesis. Research suggests that PUFA level reduction is related to schizophrenia (Berger et al., 2006) . Concordant with these findings, omega-3 PUFA may have positive effects in the treatment of schizophrenia (Emsley et al., 2002; Peet, 2008) .
(ii) Glutamate. Besides dopamine, glutamate is thought to play a role in schizophrenia . On the basis of the hypothesis that the glutamatergic system may be compromised in schizophrenia, the use of N-methyl-D-aspartate (NMDA) receptor modulators may compensate for alterations in the glutamate system (Singh and Singh, 2011) . Agents with coagonistic properties to (glutaminergic) NMDA receptors are glycine (full, endogenous agonist), D-serine (full, endogenous agonist), D-cycloserine (partial, exogenous agonist), D-alanine (partial, endogenous agonist), and sarcosine (= methylglycine, acting as a reuptake inhibitor of glycine and source of glycine). The glycine transporter-1 (GlyT-1) plays a pivotal role in maintaining the glycine concentration within synapses at a subsaturating level. Sarcosine is a GlyT-1 inhibitor, meaning that its presence results in increased glycine concentrations. Lower cerebral glycine levels are suggested to be found in patients with schizophrenia. The administration of sarcosine is therefore proposed to relieve symptoms of schizophrenia when added to nonclozapine antipsychotics . Whereas the mechanisms of NAC are now beginning to be understood, NAC is probably exerting benefits beyond being a precursor to the antioxidant glutathione, also modulating glutamatergic, neurotropic, and inflammatory pathways (Dean et al., 2011) .
(iii) Eastern (Chinese and ayurvedic) herbs. Eastern herbs are provided in the context of treatment with complete systems of medicine that evolved over thousands of years, such as TCM and Ayurveda. These treatments include prescription of herbal compounds, massage, diet, acupuncture, and the regulation of lifestyle (Clifford, 1994; Kaptchuck, 2000) . Most clinical studies were performed on acupuncture (beyond the scope of this review) and on herbal compounds.
(iv) B vitamins. Nobel laureate Linus Pauling proposed a way of understanding and treating psychiatric disorders by correcting malfunctions in the body's chemistry, calling this approach "orthomolecular psychiatry" (Pauling, 1968) . His idea was partly built on studies by Osmond and Hoffer (1962) and Hoffer and Osmond (1964) , reporting good results when treating patients with schizophrenia with large doses of vitamins, especially vitamin B3. Hoffer (1971 Hoffer ( , 1972 published two more positive results with B vitamins. However, attempts to replicate his findings seem to have failed (Ban and Lehmann, 1975; Wittkopp and Abuzzahab, 1972) . The contradicting findings may be explained because vitamine B is suggested to be effective in early psychosis but not in chronic schizophrenia (Hoffer and Osmond, 1964) . One of the proposed mechanisms is abnormal one-carbon metabolism due to vitamin deficiencies (Hoffer, 2008) . Variable levels of the components of one-carbon metabolism (folic acid [= vitamin B9] and vitamin B12) and consequently altered levels of homocysteine and phospholipid DHA have been reported both in medicated patients and in medication-naive first-episode psychotic patients (Kale et al., 2010) . Folate status in patients with schizophrenia correlates inversely with negative symptoms .
(v) Antioxidants. Oxygen is essential in life but also generates reactive molecules (so-called free radicals) throughout the body. These free radicals are potentially harmful because they can damage essential molecules such as DNA and the enzymes necessary for proper cell functioning. Antioxidants may capture these reactive free radicals and convert them back to less reactive forms of the molecules (Singh 
Item
Description Scoring Randomization Was the study described as randomized (this includes the use of words such as randomly, random, and randomization)?
point
Was the method to generate the sequence of randomization described and appropriate (table of random numbers, computer generated, etc)?
+1 point
Was the method to generate the sequence of randomization described inappropriate (patients were allocated alternately, or according to date of birth, hospital number, etc)? The Scoring of effects: + = positive effect, − = negative effect, 0 = no effect. et al., 2010). Research suggests that oxidative damage (maybe due to defective enzyme systems) may contribute to the course and outcome of schizophrenia (Fendri et al., 2006; Mahadik and Mukherjee, 1996; Mahadik et al., 2001) and is already present in patients with firstepisode psychosis (Flatow et al., 2013) . Ascorbic acid (vitamin C), an antioxidant vitamin, plays an important role in protecting free radical-induced damage in the body. It is present in brain tissue and dopamine-dominant areas in higher concentrations compared with other organs (Harrison and May, 2009) . Ginkgo biloba, an extract of the leaves of the ginkgo biloba tree, is also suggested to have antioxidant properties (Maclennan et al., 2002) , improving brain circulation at the microvascular level (Kuboto et al., 2001; Sun et al., 2003; Yan et al., 2008) and, thus, improving outcome in psychosis.
Long-term treatment with antipsychotics is associated with a variety of movement disorders, including tardive dyskinesia (TD). Both dopamine receptor supersensitivity and oxidative stress-induced neurotoxicity in the nigrostriatal system are suggested to be involved in its pathogenesis (Kulkarni and Naidu, 2003) . The pineal hormone melatonin is a potent antioxidant and attenuates dopaminergic activity in the striatum and dopamine release from the hypothalamus (Shamir et al., 2001) . Thus, treatment with antioxidative agents may have a beneficial effect for both treatment of psychotic symptoms and prevention of TD. Vitamin E has been suggested for TD because it is a lipid-soluble antioxidant that decreases free radical formation (Herrera and Barbas, 2001 ).
Risk of Bias Assessment
Two assessors (A.A.B.V. and N.K.V.) independently rated the methodological quality of the eligible RCTs using the Jadad scale (Jadad et al., 1996) . Interrater agreement on the Jadad scores before consensus discussion amounted to 0.83. Besides, H.J.R.H. independently rated a random selection of 17 papers (15%) from the selected RCTs. Interrater agreement of all three assessors was 0.71. Any scoring disagreements between the assessors were resolved through consensus discussion between these three authors. The 110 RCTs with a Jadad score of 3 or higher were included in the current review, categorized into six groups (see the Classification of agents section).
For each of the 110 studies fulfilling the selection criteria, the following assessments were made: which natural agent was used; was this combined with antipsychotics, and if so, which antipsychotics and what dosage; the effect of the natural agent on negative, positive, cognitive, depressive, and general symptoms and on adverse effects of antipsychotics; possible adverse effects of the natural agent; number of participants in the study; control group characteristics; number of dropouts; study duration; and Jadad score. The results are shown in Table 3 .
Results
In total, 110 RCTs that matched the inclusion criteria were identified. Detailed effects are given in Table 3 . Most of the studies were performed in the United States, followed by (in decreasing order) Israel, Canada, Taiwan, China, India, United Kingdom, Australia, Iran, South Africa, Switzerland, the Netherlands, Austria, Ireland, Korea, and Norway.
(i) Omega-3 Fatty Acids
Eleven RCTs on omega-3 were included (Bentsen et al., 2013; Berger et al., 2007; Emsley et al., 2002 Emsley et al., , 2006 Emsley et al., , 2008 Fenton et al., 2001; Manteghiy et al., 2008; Peet et al., 2001; Peet and Horrobin, 2002; Toktam et al., 2010; Vaddadi et al., 1989) , and one combined omega-3 with vitamins E and C (Bentsen et al., 2013) . In studies combining antipsychotics with omega-3 PUFA, one (from five) study on negative symptoms in schizophrenia found some positive effect (in patients using clozapine; Peet and Horrobin, 2002) , two (from four) found some positive effect on positive symptoms (Peet et al., 2001; Peet and Horrobin, 2002 ; one only in patients using clozapine [Peet and Horrobin, 2002] ), one (from two) on cognitive symptoms (Vaddadi et al., 1989) , none (from three) on depressive symptoms, and four (from eight) on general psychopathology (Emsley et al., 2002; Peet et al., 2001; Peet and Horrobin, 2002; Vaddadi et al., 1989 ; one only in patients using clozapine [Peet and Horrobin, 2002] ). One (from one) study on omega-3 PUFA without antipsychotics reported a decrease of positive symptoms (Peet et al., 2001) . Three (from six) reported less adverse effects of antipsychotics (EPS and/or dyskinesia) (Berger et al., 2007; Emsley et al., 2002; Vaddadi et al., 1989) . Two studies reported less use of antipsychotics in the omega-3 PUFA group (Berger et al., 2007; Peet et al., 2001) . One study reported an increase in positive symptoms by omega-3 (EPA), but only among those with low levels of red blood cell PUFA. This effect disappeared when EPA was combined with vitamin E and vitamin C (Bentsen et al., 2013) . Some nonsevere adverse effects of omega-3 PUFA were reported, such as mild gastrointestinal problems and increased bleeding time.
(ii) Glutamate improvement of positive symptoms in one and worsening in another study (from seven) ; and little or no effect on cognitive and depressive symptoms or general psychopathology and no improvement of adverse effects of antipsychotics was shown. Five (from five) studies found no improvement of adverse effects of antipsychotics Duncan et al., 2004; Goff et al., 2005; Heresco-Levy et al., 2002; Van Berckel et al., 1999) . No studies were reported on D-cycloserine without antipsychotics. No adverse effects of D-cycloserine were reported.
The only study on D-alanine reported positive effects when added to antipsychotics on negative, positive, cognitive, and general symptoms, but no effect on depressive symptoms . No effect on adverse effects of antipsychotics was found. Adverse effects of D-alanine (insomnia and nausea) were reported.
All three studies combining sarcosine with antipsychotics (not clozapine) found positive effects in almost all symptom domains Tsai et al., 2004) . When combined with clozapine (one study), no treatment effects were found . In addition, when given without antipsychotics (one study), sarcosine did not improve symptoms . Sarcosine did not improve adverse effects of antipsychotics in four (from four) studies Tsai et al., 2004) . Adverse effects of sarcosine included weight gain, insomnia, palpitations, dizziness, and sedation.
One large study on NAC added to antipsychotics reported improved positive symptoms but no improvement of negative, cognitive, or general symptoms and no improvement of adverse effects of antipsychotics , whereas one small study found some improvement of cognitive symptoms . The large study reported that there were no adverse effects, and in the small study , occurrence of any adverse effect was not mentioned.
(iii) Eastern (Chinese and Ayurvedic) Herbs
Many studies on Eastern herbs were found, but only six had a Jadad score of three or higher (Chen et al., 2008a (Chen et al., , 2008b (Chen et al., , 2009 Mahal et al., 1976; Mundewadi et al., 2008; Naidoo, 1956) . One old study on reserpine found "clinical improvement" after 11 weeks compared with placebo in 80 patients not treated with antipsychotics but with electroconvulsice therapy (Naidoo, 1956) . Several adverse effects were reported: nasal congestion, periorbital edema, diarrhea, epigastric pain, salivating, pseudo-Parkinsonian state, severe headaches, and deep pains in limbs. Another old study (Mahal et al., 1976) found positive effects of brahmyadiyoga without antipsychotics compared with placebo and equal to chlorpromazin in 136 patients with schizophrenia (Mahal et al., 1976) ; no adverse effects were reported. Four (from six) more recent studies found significant effects on general psychopathology when adding ayurvedic herbs (reserpine: one study [Naidoo, 1956] ; bacopa monnieri and nardostachys jatamansi: one study [Mundewadi et al., 2008] ; a mixture of 13 Chinese herbs: two studies [Chen et al., 2008a [Chen et al., , 2008b [Chen et al., , 2009 ) to antipsychotics.
The ayurvedic herbs were compared with 10 mg of olanzapine in a 76-week noninferiority study in 200 patients. No statistically significant differences were found between both groups examining improvement of positive and negative symptoms and general psychopathology. The ayurvedic group had less weight gain (Mundewadi et al., 2008) . Two large studies by Chen et al. (2008a Chen et al. ( , 2008b Chen et al. ( , 2009 ) of a mixture of 13 Chinese herbs found an improvement on general psychopathology. When kidney yang was added to risperidone, an improvement on cognitive and depressive symptoms was found in one study (from two) (Chen et al., 2008a (Chen et al., , 2009 . One study found no effect of the Chinese herb sarsasapogenin compared with placebo when added to risperidone on positive, negative, and cognitive symptoms or general psychopathology in 90 patients during 8 weeks (Xiao et al., 2011) . Many different nonsevere adverse effects were reported (e.g., gastrointestinal, drowsiness, and insomnia).
(iv) B Vitamins
Nineteen RCTs on B vitamins added to antipsychotics (Ananth et al., 1972 (Ananth et al., , 1973 Deutsch et al., 1977; Godfrey et al., 1990; Hill et al., 2011; Joshi, 1982; Kline et al., 1967; Lerner et al., 2001 Lerner et al., , 2002 Lerner et al., , 2004 Lerner et al., , 2007 Levine et al., 2006; McGrath et al., 1972; Meltzer et al., 1969; Miodownik et al., 2006; Petrie et al., 1981; Ramsay et al., 1970; Roffman et al., 2013; Sacks et al., 1989; Wittenborn et al., 1973) and one on B3 without antipsychotics (Greenbaum 1970) were found. B1 showed some positive effect on general psychopathology (when combined with B6 and B12) in one study (Joshi, 1982) and on positive and negative symptoms in another (Sacks et al., 1989) . B3 showed improved general psychopathology in three (from nine) studies (Ananth et al., 1972 (Ananth et al., , 1973 Petrie et al., 1981) . B6 improved general psychopathology in four (from five) studies (Ananth et al., 1973; Lerner et al., 2004; Miodownik et al., 2006; Petrie et al., 1981) . In one study, general psychopathology improved after the administration of methylfolate (Godfrey et al., 1990) . One study reported no effect of B9 (folic acid) (Hill et al., 2011) . Another study showed a positive effect of combined B6, B9, and B12 on positive, negative, and cognitive symptoms (Levine et al., 2006 ). Yet, another study showed improved negative symptoms by adding B9 (folic acid) and B12 to antipsychotics, but only in those with a specific genotype (Roffman et al., 2013) . B6 improved extrapyramidal adverse effects of antipsychotics (TD and neuroleptic induced akathisia) in four (from four) studies (Lerner et al., 2001 (Lerner et al., , 2002 (Lerner et al., , 2004 (Lerner et al., , 2007 Miodownik et al., 2006) . In one study on B3 in 57 children without antipsychotics, cognition and general psychopathology had not improved after 6 months (Greenbaum, 1970) . Most B vitamins induced modest adverse effects, especially skin flushing and abnormal liver function induced by vitamin B3 and B6.
(v) Antioxidants
Two RCTs on vitamin C were found (Bhavani et al., 1962; Dakhale et al., 2005) . One reported improved general psychopathology and reduced adverse effects (reduced serum malondialdehyde; a lipid peroxidation product) when added to olanzapine (10 mg), quetiapine (200 mg), or ziprasidone (40 mg) after 8 weeks (Dakhale et al., 2005) . One study without antipsychotics found no effect on cognition or motor functioning after 10 days (Bhavani et al., 1962) . Both studies reported no adverse effects of vitamin C.
Four studies on ginkgo biloba were found (Zhang et al., 2001a (Zhang et al., , 2001b (Zhang et al., , 2006 (Zhang et al., , 2011b Zhou et al., 1999) . Three (from four) studies found improved positive symptoms (Zhang et al., 2001a (Zhang et al., , 2001b (Zhang et al., , 2006 (Zhang et al., , 2011b Zhou et al., 1999) , two (from three) found improved general psychopathology (Zhang et al., 2001a; Zhou et al., 1999) , and four (from four) reported no improvement of negative symptoms when added to antipsychotics (Zhang et al., 2001a (Zhang et al., , 2001b (Zhang et al., , 2006 (Zhang et al., , 2011a Zhou et al., 1999) . In all four studies, adverse effects of antipsychotics improved (behavioral toxicity, symtoms of nervous system, and TD). No adverse effects of ginkgo were reported.
Thirteen studies of vitamin E were found (Adler et al., 1993 (Adler et al., , 1999 Akhtar et al., 1993; Dabiri et al., 1994; Dorevitch et al., 1997a Dorevitch et al., , 1997b Egan et al., 1992; Elkashef et al., 1990; Lam et al., 1994; Lohr and Caligiuri, 1996; Salmasi et al., 2009; Schmidt et al., 1991; Shriqui et al., 1992) . Six (from 13) studies for reducing EPSs, while using antipsychotics, showed a decrease of TD (Adler et al., 1993; Akhtar et al., 1993; Dabiri et al., 1994; Egan et al., 1992; Elkashef et al., 1990; Lohr and Caligiuri 1996) and EPS (one study; Elkashef et al., 1990) , and those with shorter duration of TD seemed to improve more; no adverse effects of vitamin E were reported, except mild diarrhea in two studies. Five (from five) reported no effect on general psychopathology (Adler et al., 1999; Dorevitch et al., 1997a; Elkashef et al., 1990; Lam et al., 1994; Lohr and Caligiuri, 1996) . One study of melatonin for TD reported a decrease of TD and no adverse effects (Shamir et al., 2001 ).
(vi) Other Substances
Agents that did not fit in the five aforementioned categories were classified in this residual category. A total of 16 high-quality RCTs have been performed on multivitamins (Altman et al., 1973; Vaughan and McConaghy, 1999) , hormones (DHEA; Nachshoni et al., 2005; Ritsner, 2010; Ritsner et al., 2006; Strous et al., 2003 Strous et al., , 2007 , pregnenolone (PREG; Ritsner, 2010) , estradiol (Akhondzadeh et al., 2003; Kulkarni et al., 2008 Kulkarni et al., , 2011 , protilerin (thyrotropin-releasing hormone) (Prange, 1979) , testosterone (Ko et al., 2008) , inositol (Levine et al., 1994) , gamma-hydroxybutyrate (GHB; Levy et al., 1983; Schulz et al., 1981) and des-tyr-gamma-endorphin (Verhoeven et al., 1979) . Two (from five) studies on DHEA added to antipsychotics showed improvement of negative symptoms (Ritsner et al., 2006; Strous et al., 2003) , two (from three) on positive symptoms (Ritsner, 2010; Ritsner et al., 2006) , one (from three) on cognition (Ritsner et al., 2006) , two (from two) on depression (Ritsner et al., 2006; Strous et al., 2003) , and one (from four) on general functioning (Strous et al., 2003) . Three (from four) improved adverse effects of drugs (Nachshoni et al., 2005; Ritsner, 2010; Strous et al., 2007) . In one study of 30 patients with schizophrenia, using either 5 g of 1% testosterone gel or a placebo added to a fixed dosage of antipsychotic medication over a period of 4 weeks, negative symptoms improved without adverse effects (Ko et al., 2008) . One (from one) small study (N = 12) on protilerin found improved general psychopathology (Prange, 1979) . Three (from three) studies on estradiol showed improvement of general psychopathology (Akhondzadeh et al., 2003; Kulkarni et al., 2008 Kulkarni et al., , 2011 , two (from three) of positive symptoms (Akhondzadeh et al., 2003; Kulkarni et al., 2008) , one (from one) of improved cognition (Kulkarni et al., 2008) , and none (from three) of negative symptoms.
One (from one) small study (N = 14) on inositol found no effect on positive or negative symptoms (Levine et al., 1994) . Two (from two) studies on GHB found no improvement of general psychopathology (Levy et al., 1983; Schulz et al., 1981) . One (from one) very small (N = 6) study on des-tyr-gamma-endorphin found improvement on general psychopathology and positive symptoms (Verhoeven et al., 1979) . No serious adverse effects of these agents were reported.
One study (of two) on artemisinin (a natural medicine against malaria) found a significant effect on negative symptoms and clinical global impression, but no effect on positive or cognitive symptoms or on general psychopathology in first-episode treatment-naive patients that were treated with risperidone (Dickerson et al., 2011; Wang et al., 2014) . The study of Dickerson et al. (2011) did not demonstrate clinical benefit of adjunctive artemisinin for schizophrenia symptoms.
DISCUSSION
This review describes the effects of natural agents in the treatment of psychotic disorders and of undesired effects of antipsychotics. Some studies suggest that glycine, sarcosine, NAC, several Chinese and ayurvedic herbs, ginkgo biloba, estradiol, and vitamin B6 may be effective for psychotic symptoms when added to antipsychotics (glycine not when added to clozapine). We found inconclusive or no evidence for omega-3 fatty acids, D-serine, D-alanine, D-cycloserine, other B vitamins, vitamin C, DHEA, PREG, inositol, GHB, and destyr-gamma-endorphin when added to antipsychotics. Reserpine without antipsychotics seemed effective in one old study but was poorly tolerated. Ayurvedic herbs seemed equally effective as olanzapine in only one study. Other agents as monotherapy (vitamin B3, vitamin C, sarcosine, glycine, and protilerin) were not effective or had only been tested in single or small trials. For alleviation of adverse effects, ginkgo and vitamin B6 seemed effective for TD and neuroleptic induced akathisia (NIA). The evidence for reducing some adverse effects of antipsychotics by omega-3 fatty acids, melatonin, and DHEA was inconclusive.
Apart from reserpine, all natural compounds studied caused no or mild undesired adverse effects. There is inconclusive evidence for improved outcome by combining omega-3 fatty acids with antipsychotics in schizophrenia. Earlier reviews reported similar conclusions (Boskovic et al., 2011; Irving et al., 2006; Tsalamanios et al., 2006) . A metaanalysis of randomized placebo controlled trails showed a modest, nonsignificant, beneficial effect of fatty acids in schizophrenia (Fusar-Poli and Berger, 2012) .
Glycine and sarcosine combined with antipsychotics may reduce negative symptoms, but not when combined with clozapine and neither as monotherapy. Inconclusive evidence was found for D-cycloserine and D-serine on clinical improvement. Our results concur with two reviews (Singh and Singh, 2011; Tsai and Lin, 2010) and are in line with a Cochrane review (Tiihonen and Wahlbeck, 2006) . Conflicting results from studies on drugs targeting the glutamate/NMDA system may be explained by complicated dose-effect relationships, as recently found in studies with the GlyT-1 transporter antagonist bitopertin (Umbricht et al., 2013) .
By adding Chinese or ayurvedic herbs to antipsychotics, general psychopathology may improve. One study (of two) on artemisinin (a natural medicine against malaria) found a significant effect on negative symptoms and clinical global impression, but no effect on positive or cognitive symptoms or on general psychopathology in first-episode treatment-naive patients who were treated with risperidone (Wang et al., 2014; Dickerson et al., 2011) . The study of Dickerson et al. (2011) did not demonstrate clinical benefit of adjunctive artemisinin for schizophrenia symptoms. Rathbone et al. (2007) state that "the results suggest that combining Chinese herbal medicine with antipsychotics is beneficial." Another Cochrane review (Agarwal et al., 2007) concludes that "ayurvedic medication may have some effects for treatment of schizophrenia, but has been evaluated only in a few small pioneering trials." These results need further exploration and pharmacological differentation, as Chinese and ayurvedic herbs include hundreds of species combined in thousands of different combinations and are prescribed in a fundamentally different way than Western medicines (Clifford, 1994; Kaptchuck, 2000) . The combined approach using knowledge from both conventional and Chinese medicine seems promising, as it may lead to innovation (Van der Greef, 2011) and possibly to improved outcomes (Zhang et al., 2011b) .
Inconsistent beneficial outcomes of studies on B vitamins were identified, especially when given as a combination of B1, B3, B6, B9, and/or B12 with antipsychotics. One review concluded that no adequate support for the efficacy of B vitamins in schizophrenia can be identified (Kleijnen and Knipschild, 1991) . Most studies with positive effects in our review, however, were published after the aforementioned review was published. Most convincing evidence was found for vitamin B6 added to antipsychotics, shown to be effective in diminishing general psychopathology and TD.
The findings on the efficacy of vitamin C for schizophrenia in only two RCTs were inconsistent, hindering definite conclusions. The efficacy of vitamin E on TD remains inconclusive, as only half of the included studies found some positive results. Even so, a meta-analysis by Boskovic et al. (2011) claimed, "Vitamin E could potentially improve TD." This may be due to the finding that those with a short history of TD tend to improve more than those with a longer history of TD. A Cochrane review in 2011 (Soares et al., 2011) came to a similar conclusion: "small trials of limited quality suggest that vitamin E may protect against deterioration of TD. There is no evidence that vitamin E improves symptoms of this problematic and disfiguring condition once established."
Ginkgo biloba seems to benefit patients with schizophrenia in several ways when added to antipsychotics. Several studies suggested evidence for improving symptoms in various domains, especially an effect on positive symptoms and the reduction of adverse effects of antipsychotics.
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On melatonin, one study provided preliminary evidence for diminishing TD (Shamir et al., 2001) . As TD is difficult to investigate because of the fluctuating symptom severity, this study needs replication.
Some inconsistent evidence was found on improved outcomes by several hormones (DHEA, PREG, and testosterone) in schizophrenia, not allowing final conclusions. A Cochrane review on DHEA/ testosterone drew a similar conclusion (Elias and Kumar, 2007) . For estradiol, a Cochrane review reported no convincing evidence over placebo (Chua et al., 2005) . Since then, two studies found that estradiol improves positive (but not negative) symptoms and general psychopathology in schizophrenia when added to antipsychotics (Kulkarni et al., 2008 (Kulkarni et al., , 2011 , however only in women of childbearing age. Therefore, using estradiol in schizophrenia warrants further study.
Limitations
There are several methodological limitations. First, the wide scope of this review allows only general descriptions of included studies in six domains. Second, it is unclear to which extent our findings are influenced by publication bias, in favor of publication of studies with positive results. Third, we used the Jadad score to select only RCTs of high quality (with a score of three or higher, as is in accordance with other reviews [e.g., see Thirthalli et al., 2016] ). However, the Jadad score is not a perfect tool because it does not judge the selection of subjects, the sample size and power, and the quality of the data analyses. Therefore, RCTs with a Jadad score of 3 or higher might still have methodological weaknesses, which hamper drawing firm conclusions. Fourth, some studies (e.g., Bhavani et al., 1962; Greenbaum 1970; Naidoo, 1956) were done in the pre-Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition (DSM-3) era, when standards of care and diagnostics may have been of lower quality than nowadays, which hampers interpretation of their results. Fifth, in most of the studies included, effect sizes were not provided nor was it possible to calculate them, which makes it difficult to compare the results or to estimate the clinical relevance of some of the findings. Sixth, it cannot be ruled out that some of the studies were underpowered, which might have hampered finding a significant effect.
Clinical Implications
Clinicians need to be aware that patients often use natural medicines without medical prescription, whereas some patients assume that natural is better than chemical and causes fewer adverse effects. Although beneficial effects may occur, this is certainly not always true. Some natural agents that may be suggested for treatment of psychotic disorders are toxic to humans (Topliss et al., 2002) , and some herbal medicines can cause adverse effects or interact with medication (Ernst, 2003b) . Only 3% of the user population is aware of the potential risks of interactions between herbs and prescription medication (Walter and Rey, 1999) . From a medical perspective, it is therefore important to know what patients buy and try. Another concern are the media reports on contamination of Chinese herbs with heavy metals. However, after investigation of 334 samples, Harris et al. (2011) conclude that "the vast majority (95%) of medications in this study contained levels of heavy metals or pesticides that would be of negligible concern." Because of these concerns, patients want their medical doctors to advise them on complementary (or natural) medicines (Gray et al., 1998; Hoenders et al., 2006) . The World Health Organization (2013) has repeatedly advised its member states to "formulate national policy and regulation for the proper use of CAM and its integration into national health care systems; establish regulatory mechanisms to control the safety and quality of products and of CAM practice; create awareness about safe and effective CAM therapies among the public and consumers" and "promote therapeutically sound use of appropriate Traditional Medicine by practitioners and consumers." Respecting patients' opinions and informing them may also improve the therapeutic relationship (Stevinson, 2001 ) and thus enhance treatment outcome (Gill, 2013; Koenig, 2000) , which depends on the quality of the therapeutic alliance (Baldwin et al., 2007) . This review gives clinicians and patients an overview of the results of RCTs, which fit a minimal level of quality (minimum Jadad score of 3), on the efficacy and safety of natural medicines for psychotic disorders. However, many questions about clinical use (e.g., dosage, safety, interactions, and quality) remain unanswered.
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